PeerView Heart, Lung & Blood CME/CNE/CPE Audio Podcast-logo

PeerView Heart, Lung & Blood CME/CNE/CPE Audio Podcast

Education Podcasts

PeerView (PVI) is a leading provider of high-quality, innovative continuing education (CME/CE/CPE and MOC) for clinicians and their interprofessional teams. Combining evidence-based medicine and instructional expertise, PeerView activities improve the knowledge, skills, and strategies that support clinical performance and patient outcomes. PeerView makes its educational programming and expert-led presentations and symposia available through its network of popular podcast channels to support specific specialties and conditions. Each episode includes a link to request CME/CE credit for participation. PeerView is solely responsible for the selection of topics, the preparation of editorial content, and the distribution of all materials it publishes.

PeerView (PVI) is a leading provider of high-quality, innovative continuing education (CME/CE/CPE and MOC) for clinicians and their interprofessional teams. Combining evidence-based medicine and instructional expertise, PeerView activities improve the knowledge, skills, and strategies that support clinical performance and patient outcomes. PeerView makes its educational programming and expert-led presentations and symposia available through its network of popular podcast channels to support specific specialties and conditions. Each episode includes a link to request CME/CE credit for participation. PeerView is solely responsible for the selection of topics, the preparation of editorial content, and the distribution of all materials it publishes.

Location:

United States

Description:

PeerView (PVI) is a leading provider of high-quality, innovative continuing education (CME/CE/CPE and MOC) for clinicians and their interprofessional teams. Combining evidence-based medicine and instructional expertise, PeerView activities improve the knowledge, skills, and strategies that support clinical performance and patient outcomes. PeerView makes its educational programming and expert-led presentations and symposia available through its network of popular podcast channels to support specific specialties and conditions. Each episode includes a link to request CME/CE credit for participation. PeerView is solely responsible for the selection of topics, the preparation of editorial content, and the distribution of all materials it publishes.

Language:

English


Episodes

Sagar Lonial, MD, FACP / Praneetha Thulasi, MD - Targeting Ocular Toxicity in Multiple Myeloma: Opportunities for Ophthalmology-Oncology Collaboration

1/13/2021
Go online to PeerView.com/DMW860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, two experts, an oncologist and ophthalmologist, discuss the intricacies of ocular toxicities associated with multiple myeloma and explore the importance of collaborating when managing patients who are being treated with novel therapeutics. Upon completion of this activity, participants should be better able to: Identify ocular complications...

Duration:01:00:24

Ian W. Flinn, MD, PhD / Caron Jacobson, MD / Preetesh Jain, MBBS, MD, DM, PhD -Rewriting Patient Care in Mantle Cell Lymphoma: How Innovative Therapy Is Poised to Challenge Conventional Treatment

1/11/2021
Go online to PeerView.com/MBT860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The recent emergence and regulatory approval of multiple novel agent classes, such as Bruton’s tyrosine kinase (BTK) inhibitors and immunomodulatory drugs (IMiDs), in the management of mantle cell lymphoma (MCL) has offered clinicians and patients a greater variety of effective therapeutic options in this challenging clinical setting. At the same time,...

Duration:01:01:53

Steven Fishbane, MD / Wendy L. St. Peter, Pharm.D, FCCP, FNKF, FASN - HIF-PH Inhibitors for Anemia in Chronic Kidney Disease: What Are Their Implications in Health-System Pharmacy?

1/8/2021
Go online to PeerView.com/HBK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity based on a recent live web broadcast, a multidisciplinary panel explores the latest data for HIF-PH inhibitors and examines their efficacy and safety in treating anemia in patients with chronic kidney disease (CKD). The panel also shares evidence-based strategies and describes new models of care for managing patients with CKD-associated anemia,...

Duration:01:19:17

Nathan H. Fowler, MD - Building New Management Models for NHL Care: Tumor Board Insights on Innovative Therapeutics in FL and DLBCL

1/8/2021
Go online to PeerView.com/DJX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) provide learners with a clinical grounding on how new science is changing FL and DLBCL management. The panel explores important factors in the selection and use of newer therapeutics and provides a concise take on the evidence that has led to the regulatory approval...

Duration:01:25:11

Professor David I. Marks, MB, MS, FRACP, PhD, FRCPath - Exploring Antibody Therapy in ALL: How and Why to Integrate Antibody-Based Treatment Into Patient Management

1/8/2021
Go online to PeerView.com/VAY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, leading hematology-oncology experts discuss the most recent clinical evidence supporting modern antibody options in acute lymphoblastic leukemia (ALL), explore their increasing therapeutic applications, and gauge the progress in improving patient outcomes across a range of ALL populations and treatment settings. Upon completion of this...

Duration:01:34:02

Sean Pokorney, MD, MBA - Improving Recognition of Nonvalvular Atrial Fibrillation to Reduce the Risk of Preventable Stroke: A Visual Guide for Clinicians

1/8/2021
Go online to PeerView.com/PFC860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. This activity has been designed to meet the educational needs of family medicine and internal medicine physicians, cardiologists, nurse practitioners, physician assistants, and other clinicians involved in the management of patients with or at risk for NVAF. Upon completion of this activity, participants should be better able to: Employ various evidence-based...

Duration:00:40:45

Javed Butler, MD, MPH, MBA - Making the Case for Treating Iron Deficiency in Patients With Heart Failure

1/8/2021
Go online to PeerView.com/BFV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in cardiovascular diseases and heart failure (HF) research presents a patient case to explore current evidence-based recommendations for diagnosing iron deficiency (ID) to encourage timely and appropriate treatment to improve outcomes in patients with HF. Upon completion of this activity, participants should be better able to:...

Duration:00:35:33

Professor Ian M. Adcock, PhD, FRSB, FBPhS, FERS - Navigating the Relationship Between Type 2 Inflammation and Uncontrolled, Moderate to Severe Asthma: Identifying Eligible Patients for Targeted Biologic Therapy

1/7/2021
Go online to PeerView.com/KGQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an asthma expert discusses the relationship between type 2 inflammation and moderate to severe asthma and the use of targeted biologic therapies as treatment. Upon completion of this activity, participants should be better able to: Explain the relationship between type 2 inflammation and moderate-to-severe asthma, biomarkers such as blood...

Duration:00:25:47

"Eric Gapud, MD, PhD / Michael E. Wechsler, MD - Improving Recognition and Management of EGPA: A Multidisciplinary Approach to Individualizing Treatment"

1/6/2021
Go online to PeerView.com/DKK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare multisystemic disorder that can be fatal if left untreated. EGPA is characterized by moderate-to-severe asthma, peripheral blood eosinophilia, mononeuropathy or polyneuropathy, pulmonary infiltrates, paranasal sinus abnormalities, and extravascular eosinophils or eosinophilic vasculitis. Optimal...

Duration:01:00:08

Naval Daver, MD / Harry P. Erba, MD, PhD / Tara Lin, MD / Gail J. Roboz, MD -How I Think, How I Treat in the New Age of AML Care: Personal Perspectives on New Evidence and Innovative Therapeutics

1/4/2021
Go online to PeerView.com/CHU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Led by a panel of expert clinicians, this “How I Think, How I Treat” activity explores the practice-changing evidence that has validated innovative approaches to managing high-risk AML; the use of targeted agents in mutation-defined disease and older populations; and the steady progress being made with antibody-based options for AML. Throughout, the experts...

Duration:01:39:38

Jonathan A. Bernstein, MD - Understanding the Relationship Between Type 2 Inflammation, Atopic Diseases, and Treatment Selection: Practical Strategies for the Healthcare Team to Improve Patient Care

1/4/2021
Go online to PeerView.com/DRD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in atopic diseases discusses the relationship between type 2 inflammation and atopic diseases, as well as therapeutic options and strategies to improve patient quality of life. Upon completion of this activity, participants will be able to: Describe the relationship between type 2 inflammation and atopic diseases including asthma,...

Duration:00:25:53

Steven Fishbane, MD - Management of Hyperkalemia in Patients With Hemodialysis-Dependent Chronic Kidney Disease: Applying New Evidence and Best Practices for Improved Patient Outcomes

1/4/2021
Go online to PeerView.com/YAS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this infographic-based activity, an expert nephrologist discusses hyperkalemia in patients with hemodialysis-dependent chronic kidney disease (CKD) and explores the role of potassium binders in the treatment of hyperkalemia. Upon completion of this activity, participants will be able to: Differentiate currently available agents for the management of...

Duration:00:34:58

Suresh S. Ramalingam, MD, FACP, FASCO - Everything You Need to Know About Molecular Testing and Targeted Therapies in NSCLC: Essential Guidance for Modern Patient-Centered Precision Lung Cancer Care

12/30/2020
Go online to PeerView.com/VVS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The targeted therapy landscape for non–small cell lung cancer (NSCLC) has evolved considerably in recent years, with far-reaching implications for oncologists, pathologists, and other members of the broader lung cancer care team, as well as for patients. This educational activity provides a comprehensive overview of the importance of performing genomic...

Duration:01:04:27

Flavia Castelino, MD / Sonye K. Danoff, MD, PhD - The Evolving Treatment Landscape of SSc-ILD: Strategies to Improve Recognition and Management

12/28/2020
Go online to PeerView.com/RWP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Systemic sclerosis (SSc) is a rare, clinically heterogeneous, multisystem disease characterized by extensive fibrosis, autoimmunity, and vascular dysfunction. Pulmonary involvement, particularly interstitial lung disease (ILD), occurs in the majority of patients with SSc and is now the number one cause of death in SSc. Before 2019, immunosuppression was the...

Duration:01:21:25

Stephen V. Liu, MD / Bhavesh Shah, RPh, BCOP - Immunotherapy in the Treatment Arsenal for Small Cell Lung Cancer, and Managed Care Implications for the "Four Ps": Patient, Provider, Pharmacy, and Plan

12/18/2020
Go online to PeerView.com/TMR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in oncology and managed care provide a foundational overview of the mechanism of action of cancer immunotherapies and why this class of agents is different from other oncologic therapies. The panel also explores how immunotherapies have revolutionized the management of cancer over the last few years, particularly the ways in which SCLC...

Duration:01:31:07

David R. Jones, MD - Turning Tides in Targeted Therapy for Early-Stage EGFR-Mutated NSCLC: Latest Data and Practical Guidance for Thoracic Surgeons and the Multidisciplinary Team on the Emerging Role of EGFR-Targeted Therapy in Resectable Lung Cancer

12/14/2020
Go online to PeerView.com/ZUJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In the era of precision medicine, genomic profiling to individualize management of patients with advanced non–small cell lung cancer (NSCLC) is paramount. Advances in targeted therapy in advanced/metastatic NSCLC have heightened interest in expanding its use into earlier stages of the disease to improve outcomes in curative intent settings. Subsequently, a...

Duration:00:57:42

Gwen A. Huitt, MD, MS - Addressing Challenges in the Treatment of Nontuberculous Mycobacterial Lung Disease: Managing Adverse Effects to Keep Patients on Therapy

12/9/2020
Go online to PeerView.com/SVG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in NTM-LD discusses diagnosing and treating a patient with NTM-LD, with the goal of maintaining treatment adherence. Upon completion of this activity, participants should be better able to: Describe the burden of treatment associated with nontuberculous mycobacterial lung disease (NTM-LD), especially adverse events that may lead to...

Duration:00:32:12

Lucia M. Novak, MSN, ANP-BC, BC-ADM, CDTC - The Art of Medicine: Creating Treatment Regimens With GLP-1 RAs to Reduce Cardiovascular Risks in Patients With T2DM

12/2/2020
Go online to PeerView.com/SVU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert on type 2 diabetes mellitus (T2DM) describes shared decision-making strategies to individualize treatment and reduce cardiovascular risks in patients with T2DM using GLP-1 receptor agonists (GLP-1 RAs). Upon completion of this activity, participants should be better able to: Review the role of, current guidance, and approved...

Duration:00:51:16

Kurt Schalper, MD, PhD - Navigating the Complexities of Biomarker Testing in the Expanding Field of Precision Immuno-Oncology: Latest Evidence, Current Challenges, and Practical Guidance for Pathologists

11/17/2020
Go online to PeerView.com/JZJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Cancer immunotherapies are demonstrating remarkable clinical activity in an increasing number of malignancies, and as the immunotherapy arsenal has continued to expand, so has the importance of predictive biomarkers to guide clinical decisions and identify patients who are most likely to benefit from specific immune checkpoint inhibitors or combinations. A...

Duration:00:59:45

Naval Daver, MD / Joseph D. Khoury, MD, FCAP - The Pathology–Oncology Partnership in AML: Identifying and Treating the Diversity of Disease Subtypes

11/13/2020
Go online to PeerView.com/PDK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert pathologist-oncologist panel discusses how modern, team-based treatment decisions are guided by the results of molecular/pathology testing across a wide range of acute myeloid leukemia (AML) settings, while also profiling how new evidence influences pathologic assessment and treatment selection across the continuum of AML care. Upon...

Duration:01:02:32